France HAS: "scrap and replace" payer system

17 December 2007

France's health care watchdog body, the HAS, has denounced current arrangements for the full reimbursement of treatment in serious and chronic diseases such as cancer and diabetes as "unreformable" by administrative or management changes. Instead, in a new report, the HAS argues that the current system needs scrapping and rapid replacement. The study is based on a review of reimbursement arrangements for 20 diseases. Overall, the full reimbursement regime for chronic conditions covers about eight million patients and accounts for three quarters of the total cost of reimbursable health spending.

The HAS is calling for the medical nature of any given condition to be eliminated from the criteria used for setting the reimbursement level. A new system should be based on "an objective measure of costs supported by the patient," the watchdog said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight